Advertisement

Search Results



Your search for all items matches 11461 pages

Showing 1 - 50


pancreatic cancer

Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment

Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the evidence for using neoadjuvant and adjuvant systemic therapies in resectable and borderline resectable pancreatic cancer.

bladder cancer

Elizabeth R. Plimack, MD, on Bladder Cancer: Management Updates

Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses selecting first- and second-line therapies for patients with advanced bladder cancer and the emerging data and role of immune checkpoint inhibitors.

lymphoma

Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

Leo I. Gordon, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses novel immunomodulatory agents and standard treatment options for patients with relapsed or refractory Hodgkin lymphoma.

issues in oncology

Paul M. Cinciripini, PhD, on Smoking Cessation in Patients With Cancer

Paul M. Cinciripini, PhD, of The University of Texas MD Anderson Cancer Center, discusses the oncologist’s role in addressing and documenting cancer patients’ smoking and cessation attempts as well as treatment advances.

head and neck cancer

David G. Pfister, MD, on HPV and Head and Neck Cancer

David G. Pfister, MD, of Memorial Sloan Kettering Cancer Center, discusses the link between human papillomavirus and oropharyngeal cancers and what is known about the effect of HPV on treatment response and outcome.

gynecologic cancers

Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer

Christina S. Chu, MD, of Fox Chase Cancer Center, discusses the link between human papillomavirus and genital cancers and what is known about the effect of HPV on treatment response and outcome.

if youre reading this it worked

TEST 2 TEST 2

TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST 2 TEST...

Guidelines Planned on Management of Immunotherapy Side Effects: ASCO and NCCN to Collaborate on Development

Given the pace of advances in immunotherapy in recent years and physicians’ need to keep up with these developments, ASCO and the National Comprehensive Cancer Network® (NCCN®) have announced a joint collaboration to publish practical clinical guidance on the management of side effects caused by...

Conquer Cancer Foundation Conquerors Circle Donors

The Conquerors Circle is the Conquer Cancer Foundation’s first-ever donor appreciation society. Donors who contribute $1,000 annually are members of the Conquerors Circle. In appreciation for their generous and loyal support of the Conquer Cancer Foundation, Conquerors Circle members receive...

An Evening for Cancer Survivors and Caregivers: Bringing Together a Community of Support

On January 26, 2017—prior to the official opening of the 2nd Annual Cancer Survivorship Symposium—cancer survivors, caregivers, patient advocates, family physicians, oncology providers, and others gathered in San Diego, California, to make connections, discuss survivorship issues, and get expert...

New ASCO Answers Fact Sheets on MDS, Bone Marrow Transplant for Your Practice

Be sure to check out new ASCO Answers fact sheets on myelodysplastic syndrome (MDS) and understanding bone marrow transplantation at Cancer.Net. These 1-page (front and back) introductions include an overview, illustrations, terms to know, and questions to ask the doctor. Find these and a library...

ASCO Research Community Forum Offers Tools, Resources to Support Cancer Research Sites

As part of ASCO’s efforts to support cancer researchers and research sites, the ASCO Research Community Forum was created in 2010 to help physician investigators and research staff overcome common barriers to conducting research and enhance their research-site operations. The Forum is a go-to...

ASCO Launches Its New Journal Dedicated to Informatics

On February 23, 2017, ASCO launched its newest online-only journal, JCO Clinical Cancer Informatics (JCO CCI). The first four articles published in JCO CCI are: 1) An editorial from JCO CCI Editor-in-Chief Debra A. Patt, MD, MPH, MBA, introducing the publication and laying out its objective of...

Mammography-Detected Small Breast Cancers May Represent Overdiagnosis, With Declining Mortality Reflecting Improved Systemic Therapy

In a study using Surveillance, Epidemiology, and End Results (SEER) data reported in The New England Journal of Medicine, H. Gilbert Welch, MD, of Dartmouth Institute for Health Policy and Clinical Practice, and colleagues found that screening mammography has resulted in a substantial increase in...

New Supportive Care Resources From NCCN Help Patients With Cancer Confront Distress

All patients with cancer experience some level of distress associated with their cancer diagnosis and the effects of the disease and its treatment—regardless of the stage of disease. Not only does distress affect a patient’s mental and psychosocial well-being, but because distress is a...

Major Pharmaceutical Companies Collaborate in NCCN Research Project

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has funded three studies in its first multi-industry collaborative research project in which Boehringer Ingelheim and Eli Lilly are collaborating with NCCN to study combination therapeutic agents in ...

SIOG 2017 Advanced Course in Treviso, Italy

The International Society of Geriatric Oncology (SIOG) has a workshop to educate young investigators in geriatric oncology research. The SIOG Advanced Course, which is held in Treviso, Italy (June 28–July 1, 2017), is our unique continuing medical education–accredited training program led by...

Future Perspectives in Geriatric Oncology: How the Young Can Care for the Old

In the upcoming decades, the number of older adults with cancer will drastically increase due to aging of Western societies.1 The risk of cancer strongly increases with age. Consequently, all future oncologists will be exposed to the challenges of caring for this heterogeneous population. Older...

hematologic malignancies

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines 126

Ruben A. Mesa, MD, of the Mayo Clinic Cancer Center, discusses molecular abnormalities and their use in the diagnosis, risk stratification, and selection of treatment for myelofibrosis.

sarcoma

Suzanne George, MD, on Soft-Tissue Sarcoma: Evolving Treatment 126

Suzanne George, MD, of Dana-Farber Cancer Institute, discusses current and emerging systemic therapies for soft-tissue sarcoma and the options for multimodality treatment.

FDA Approves Avelumab for Metastatic Merkel Cell Carcinoma

The U.S. Food and Drug Administration (FDA) today granted accelerated approval to avelumab (Bavencio) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma, including those who have not received prior chemotherapy. Avelumab is a programmed cell...

Delays in Radiotherapy for Head and Neck Cancer in Insured and Indigent Populations

In a study reported in the Journal of Oncology Practice, Thomas et al found that interruption of radiotherapy for head and neck cancer was more frequent and treatment outcomes were poorer among indigent populations vs commercially or Medicare-insured populations within a single academic health...

Celecoxib or Celecoxib/Zoledronic Acid in Men Initiating Hormone Therapy for Prostate Cancer

As reported by Mason et al in the Journal of Clinical Oncology, long-term survival results of the UK-based, multiarm, multistage platform–design STAMPEDE trial showed no survival benefit with the addition of celecoxib or celecoxib plus zoledronic acid in men initiating long-term hormone...

Anne Friedman Glauber, Cofounder of Online Pancreatic Cancer Forum, Dies at Age 63

Anne Friedman Glauber, 63, co-founder of Let’s Win, an online community for persons affected by pancreatic cancer, recently passed away at her home in New York City, after a courageous battle with the disease. Ms. Glauber’s dedication to the organization (www.letswinpc.org) helped countless...

Hematologic Malignancies
Leukemia

Financial Burden of Targeted Oral Therapy for Patients With Chronic Myeloid Leukemia

In a study reported in the Journal of Oncology Practice, Chan Shen, PhD, of The University of Texas MD Anderson Cancer Center, and colleagues found that more than three-quarters of patients receiving targeted oral therapy for chronic myeloid leukemia (CML) reached the catastrophic phase of the...

Solid Tumors
Breast Cancer

Predicting Acute Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy

In a Dutch study reported in the Journal of Clinical Oncology, van den Bogaard et al found that a model including the volume of the left ventricle receiving 5 Gy (LV-V5) might provide improved prediction of acute cardiac events in patients with breast cancer receiving radiotherapy. Prior findings...

Kidney Cancer

Intermittent Sunitinib in Metastatic Renal Cell Carcinoma

In a phase II study reported in the Journal of Clinical Oncology, Moshe C. Ornstein, MD, of Cleveland Clinic Taussig Cancer Institute, and colleagues found that an intermittent schedule of sunitinib (Sutent) may be feasible in patients with previously untreated metastatic renal cell carcinoma. In...

Solid Tumors
Prostate Cancer

Potential Surrogate for All-Cause Mortality Risk in Localized Prostate Cancer

In a study reported in JAMA Oncology, Trevor J. Royce, MD, of Harvard Radiation Oncology Program, Brigham and Women’s Hospital, and colleagues found that a prostate-specific antigen (PSA) nadir > 0.5 ng/mL may be a dominant risk factor for all-cause mortality after radiation therapy and...

Solid Tumors
Colorectal Cancer

Reducing Debilitating Symptoms of Advanced Colorectal Cancer

In a phase III trial reported in The Lancet Oncology, Tamas Hickish, MD, of Poole Hospital NHS Foundation Trust, Dorset, England, and colleagues found that treatment with MABp1, an antibody that targets interleukin 1α and exhibits antitumor activity, was associated with improvement in the composite ...

Fox Chase Junior Investigators Win Awards for Pilot Projects

Fox Chase Cancer Center is pleased to announce the results of its American Cancer Society Institutional Research Grant Pilot Project Competition for Junior Investigators. The competition was open to eligible junior faculty at Fox Chase and Temple University Hospital. The awardees are Yibin Yang, ...

Supportive Care
Palliative Care

Examining the Impact of ‘Death With Dignity’ Legislation

Despite the controversy surrounding “Death With Dignity” laws, which allow physicians to prescribe life-ending drugs to terminally ill patients, they have a long history of majority support from Americans. According to a Gallup poll taken in 2015, nearly 7 in 10 Americans (68%) agreed that...

Discrimination in Medical Education—Another Perspective

I read with great interest Dr. ­Robert E. Montenegro’s comments in the The ASCO Post, January 25, 2017, where he felt “marginalized” when questioned about his country of origin or the quality of his English. As physicians, we constantly deal in a world of uncertainties and are required to address...

Arti Hurria, MD, Named Vice Provost at City of Hope

Geriatrician-oncologist Arti ­Hurria, MD, has been named Vice Provost for Clinical Faculty at City of Hope. “I spent most of my formative years at City of Hope and was very fortunate,” said Dr. Hurria, who’s been at the medical center for 10 years. “I had mentors who helped me along the way and...

Chief Clinical Officer’s Distinguished Chair Created at City of Hope to Honor Alexandra M. Levine, MD, MACP

A significant philanthropic gift from the Campbell family of Las Vegas, Nevada, will establish a new endowed Chair to honor City of Hope’s former Chief Medical Officer Alexandra M. Levine, MD, MACP. The recipient of the Deana and Steve Campbell Chief Clinical Officer’s Distinguished Chair, to be...

Solid Tumors

Coping With an Uncommon Cancer

In April 2014, I was so sick with uncontrollable vomiting and diarrhea and severe abdominal and chest pain that I had to be hospitalized for 5 days. As I was in my late 20s and in otherwise good health, there was no easy explanation for my symptoms. After I was released from the hospital, my...

Supportive Care
Integrative Oncology
Symptom Management
Breast Cancer

Acupuncture for the Management of Hot Flashes

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, authors Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, present a case study...

Hematologic Malignancies
Multiple Myeloma

Implications of SWOG S0777 and the Future of Combination Treatments for Multiple Myeloma

The treatment of multiple myeloma is becoming increasingly complicated. This is not only because of the complexity of the disease, but also because of the increasing number of effective combination treatments and continuous development of new drugs. This has resulted in an ever-increasing number ...

Suresh Vedantham, MD, FSIR, Named President of SIR

Suresh Vedantham, MD, FSIR, an interventional radiologist and Professor of Radiology and Surgery at the Mallinckrodt Institute of Radiology at Washington University in St. Louis, assumed the office of President of the Society of Interventional Radiology (SIR) on March 7, 2017, during the Society’s ...

Hematologic Malignancies
Multiple Myeloma

Adding Bortezomib to Lenalidomide/Dexamethasone Improves Survival in Patients With Newly Diagnosed Multiple Myeloma

In the phase III SWOG S0777 trial reported in The Lancet, Brian G.M. Durie, MD, of Cedars-Sinai Samuel Oschin Cancer Center, and colleagues found that adding bor­tezomib ­(Velcade) to lenalidomide (Revlimid)/dexamethasone improved progression-free and overall survival in patients with newly...

Lung Cancer

New First-Line Options for ALK-Positive Lung Cancer on the Horizon

Anaplastic lymphoma kinase (ALK) rearrangements define a subset of non–small cell lung cancer (NSCLC) patients for whom ALK inhibitors are highly effective. In PROFILE 1014, the multitargeted ALK inhibitor crizotinib (Xalkori) was shown to be superior to platinum/pemetrexed (Alimta) chemotherapy...

Lung Cancer

Markedly Improved Progression-Free Survival With First-Line Ceritinib vs Platinum Chemotherapy in ALK-Rearranged NSCLC

In the phase III ASCEND-4 trial reported in The Lancet, Jean-Charles Soria, MD, of Institut Gustave Roussy, and colleagues found that ceritinib (Zykadia) improved progression-free survival vs platinum-based chemotherapy in the first-line treatment of advanced anaplastic lymphoma kinase...

Eric M. Horwitz, MD, Inducted Into Inaugural Class of Fellows of the American Brachytherapy Society

Eric M. Horwitz, MD, Chair of the Department of Radiation Oncology at Fox Chase Cancer Center, has been selected by the American Brachytherapy Society (ABS) as an inaugural ABS Fellow. Dr. Horwitz is among 12 fellows in the inaugural class. He will be formally recognized at the ABS 2017 Annual...

Pacritinib Update

An article in the March 10, 2017, issue of The ASCO Post reported on a presentation from the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, noting that the investigational drug pacritinib has been shown to reduce spleen volume in myelofibrosis. The article erroneously...

SSO 2017: Preclinical Trial Shows Intratumoral Vaccination Induces Antitumor Response in Pancreatic Cancer

Building on their previous research focusing on intratumoral vaccination for the most common form of pancreatic cancer, investigators from Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School have shown that in a mouse model of early-stage resected pancreatic...

A Case of Mistaken Identity

In the February 25, 2017, issue of The ASCO Post, in the article “‘Watch-and-Wait’ Strategy Does Not Compromise Survival in Selected Patients With Rectal Cancer,” a photo labeled Maxime van der Valk, MD, was incorrect.  A photo of Dr. van der Valk is shown here. Dr. van der Valk is a study...

Advertisement



Advertisement


Advertisement

click me